{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086393","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.459937+00:00","generated_at":"2026-06-12T18:14:46.138441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"uniQure Q2 net loss $68.5M; cash $628.6M; AMT-130 shows preservation of function","bullets":["Revenue $2.4M (up from $0.5M YoY); net loss $1.44/share vs $0.84 loss YoY.","Cash $628.6M (excl. $100M milestone from HEMGENIX 1st US sale received July 2023).","AMT-130 interim data: preserved clinical function vs natural history; both doses well-tolerated.","Sale of HEMGENIX royalty for up to $400M; $375M upfront received.","Appointed Walid Abi-Saab, M.D. as CMO and Jeannette Potts as CLO."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086393","json":"https://secwatch.observer/filing/0001104659-23-086393.json","markdown":"https://secwatch.observer/filing/0001104659-23-086393.md","text":"https://secwatch.observer/filing/0001104659-23-086393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923086393/0001104659-23-086393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923086393/tm2322500d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T18:14:46.138441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe973c2371273cebb68a06ff764e804d6d431f5a","claim":"uniQure N.V. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 1, 2023, uniQure N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023, and highlighting company progress.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465923086393/0001104659-23-086393-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}